Drug evaluation: AP-23573--an mTOR inhibitor for the treatment of cancer.
ARIAD Pharmaceuticals Inc is developing intravenous and oral formulations of AP-23573, a rapamycin analog and inhibitor of mTOR (mammalian target of rapamycin) that blocks the proliferation and migration of vascular smooth muscle cells, for the potential treatment of cancer, including solid and hematological forms.
Elit
Laurie
L
Juravinski Cancer Centre, 699 Concession Street, Hamilton, ON L8V 5C2, Canada, laurie.elit@hrcc.on.ca
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D011494:Protein Kinases / Q000378:metabolism*; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D013329:Structure-Activity Relationship; D058570:TOR Serine-Threonine Kinases
D000970:Antineoplastic Agents; C515074:ridaforolimus; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus